Previous Close | 12.65 |
Open | 12.86 |
Bid | 9.00 x 100 |
Ask | 0.00 x 0 |
Day's Range | 7.60 - 12.86 |
52 Week Range | 5.25 - 22.20 |
Volume | |
Avg. Volume | 1,106 |
Market Cap | 15.231M |
Beta (5Y Monthly) | 0.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.05 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.60 (4.44%) |
Ex-Dividend Date | Jan 19, 2024 |
1y Target Est | N/A |
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data fr
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript March 19, 2024 Cyclacel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-6.23, expectations were $-6.35. CYCC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARCA-Mutated Cancers – – Management to Host Conference Call at 4:30 pm ET Today – BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company dev